 

Active ingredient: Alosetron Hydrochloride 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way crossover in-vivo 

Strength: 1 mg (base) 

Subjects: Normal healthy females, general population 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way crossover in-vivo 

Strength: 1 mg (base) 

Subjects: Normal healthy females, general population 

Additional comments: 




______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Alosetron in plasma 

 

Bioequivalence based on (90% CI): Alosetron 

 

Waiver request of in vivo testing: 0.5 mg (base) based on (i) acceptable bioequivalence studies 
on the 1 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro 
dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


